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Abstract 
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inflammatory treatment based on glucocorticosteroids and calcineurin inhibitors is used for flare management and for proactive 
therapy for long-term control. Topical corticosteroids remain the mainstay of therapy, whereas tacrolimus and pimecrolimus are 
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Introduction 
Atopic eczema (AE; atopic dermatitis, eczema, 
‘Neurodermitis’ in German-speaking countries, endogenous 
eczema, neurodermatitis) is an inflammatory, pruritic, 
  
  
chronic or chronically relapsing skin disease occurring often 
in families with other atopic diseases (bronchial asthma 
and/or allergic rhinoconjunctivitis). AE is one of the most 
common non-communicable skin diseases which affects up 
to 20% of children and 2–8% of adults in most countries of 
the world. In many instances, AE begins in childhood, while 
severe cases may persist in adulthood. About one-third of 
adult cases develop in adulthood. AE is often the first step in 
the development of other atopic diseases, such as allergic 
rhinoconjunctivitis or asthma and food allergy (FA). 
Although several diagnostic criteria have been proposed 
over time, the classical Hanifin and Rajka criteria are still the 
most widely used criteria worldwide.1 There is no 
pathognomonic laboratory biomarker for diagnosis of AE. 
The most typical feature, the elevation of total or allergen-
specific IgE levels in serum or the detection of IgE-mediated 
sensitization in skin tests, is not present in all individuals 
suffering from AE; the term ‘intrinsic’ (non-IgE-associated) 
AE has been introduced to distinguish the latter group from 
‘extrinsic’ (IgE-associated) forms of AE.2 The controversy in 
terminology is going on until today and has practical 
implications regarding avoidance strategies for AE 
management. 
Apart from a strong genetic influence (80% concordance 
in monozygous twins, 20% in heterozygous twins), there are 
other characteristic features in pathophysiology. These 
include an immune deviation towards the T helper 2 (Th2) 
pathway in the initiation phase with consequent increased 
IgE production; an increased production of mediators from 
various inflammatory cells, a deficient skin barrier function 
(‘dry’ skin) due to abnormal lipid metabolism and epidermal 
structural protein formation of filaggrin and protease 
inhibitors; an abnormal microbial colonization with 
pathogenic organisms such as Staphylococcus aureus or 
Malassezia sp. (compared to Staphylococcus epidermidis in 
normal individuals) and subsequently increased 
susceptibility to skin infection; and an obvious, strong 
psychosomatic influence. 
After establishing the diagnosis of AE, the overall disease 
severity must be determined by evaluating both objective 
signs and subjective symptoms. As signs-only scores are 
lacking the subjective part of pruritus and sleep disturbance, 
composite scores assessing signs and symptoms must be used 
to assess overall disease severity.3 The classical composite 
score is the ‘Scoring of Atopic Dermatitis’ (SCORAD) 
developed by the European Task Force of Atopic Dermatitis 
(ETFAD).4 AE with a SCORAD above 50 is 
regarded as severe, while SCORAD values below 25 are 
considered as mild AE.3,5 The Patient-Oriented SCORAD 
(POSCORAD) is a tool for assessing AE severity independent 
of the physician, and the results correlate well with SCORAD.6 
In contrast, the Eczema Area and Severity Score (EASI) is a 
signs-only score assessing visible lesions only, but not the 
subjective symptoms. The Patient-Oriented Eczema Measures 
for Eczema (POEM) are a symptoms-only score to measure 
subjective symptoms, but not objective signs in clinical trials. 
The Investigators Global Assessment (IGA) is frequently used, 
but more a global assessment than a validated score. In contrast 
to SCORAD, POEM and EASI, it is based on a single global 
assessment by the investigator only. The HOME group is an 
initiative of methodologists, industry representatives, patients 
and physicians interested in outcome measures for AE, which 
has done considerable work in recommending instruments for 
measurement of the previously identified domains of AE such 
as signs, symptoms, quality of life and long-term control.7 
Most AE cases can be regarded as mild, whereas less than 
10% of patients suffer from severe eczematous skin lesions. 
This percentage of severe cases seems to be higher in the adult 
AE population.8 This guideline covers most of the important and 
relevant strategies for management of AE. 
Methods 
The guideline committee decided that these guidelines should 
strictly concentrate on therapeutic regimens and omit longer 
chapters on clinical entity, diagnosis or pathophysiology of the 
disease. This is a consensus-based S2k guideline, although it has 
an additional strong focus on evidence from the literature. 
Consensus was achieved among the nominated members of the 
European interdisciplinary expert group (Fig. 1). 
Base of the guideline 
This is an update of the 2012 guideline on atopic dermatitis.8,9 
The former, first version of this guideline had been based on the 
evidence-based national guideline from Germany,10 the HTA 
report,11 as well as the position paper of the ETFAD,12 which 
were compared and assessed. The former committee had 
decided that all these documents fulfilled enough criteria to be 
used as the base of the first version of the European Guidelines 
on Treatment of Atopic Eczema.8,9 
Database and literature search 
For this consensus-based guideline, no systematic literature 
review has been performed. During the kick-off meeting in 
Copenhagen in 2015, subgroups of two authors were determined 
among the expert panel to be responsible for the draft of specific 
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sections of the guideline by virtue of their clinical and scientific 
expertise (Table S1, Supporting Information). Discrepancies 
between the two respective authors were escalated to the steering 
committee. The subgroups were in charge of the search for best 
available evidence, the summary thereof and of critically 
appraising the evidence to inform the drafted recommendations. 
Specific inclusion or exclusion criteria for the selection of the 
evidence (such as the limitation to a certain study design) were 
not defined, and the authors were encouraged to include the 
‘best available evidence’. 
Data were included only if a reference had been published as a 
full paper in a peer-reviewed journal by March 2017, but not 
based on an abstract or a conference presentation only. 
Classification of presented studies with regard to study type 
To give the reader a general impression of the quality of the 
evidence presented in this guideline, grades of evidence were 
assigned using the system employed in the 2012 version of the 
guideline (Table 1).8,9 These need to be interpreted with caution, 
however, as the literature search that was undertaken followed a 
targeted rather than systematic approach. 
Recommendation levels (Table 2) were given only for those 
therapies available in Europe by September 2017, although the 
label did not have to specifically include AE as a licensed 
indication. Therapies not available in Europe by September 2017 
could be mentioned in the manuscript, but no formal therapeutic 
recommendation would be given for these. High-level evidence 
with a potential to significantly change current treatment 
paradigms published after these deadlines could be included upon 
vote during the final meeting of the guideline committee in 
Geneva in 2017. 
The expert panel tried to use standardized language for the 
recommendations given, but would prefer a consensus vote on 
non-standardized language over standardized language, if the 
highly variable clinical presentation of AE would suggest that a 
non-standardized wording be more useful in clinical reality from 
a patient’s or physicians perspective (see Table 3 for standardized 
wording of recommendations). 
Consensus process 
The committee designated all recommendation statements, as 
well as some especially important areas as those requiring 
consensus. Consensus conferences were held in Copenhagen in 
October 2015, in Vienna in September 2016 and in Geneva in 
September 2017. Johannes Ring acted as the moderator during all 
face-to-face meetings. 
All sections with recommendations and Tables (see Tables 4 
and 5) were discussed within the whole group, and consensus was 
defined as approval by at least 75% of the panel members. All 
consented recommendations are marked with grey boxes. 
External review 
According to the EDF standard operation procedure, all EDF 
members were invited to review the guidelines prior to the last 
internal review. The comments of the participating societies were 
forwarded to the chapter authors and considered during the last 
internal review. 
Update of the guidelines 
These guidelines will require updating approximately every three 
years, but advances in medical sciences may demand an earlier 
update. 
Target group 
This guideline has been prepared for physicians, especially 
dermatologists, paediatricians, allergists, general practitioners 
and all specialists taking care of patients suffering from AE. 
Patients and relatives should also be able to get reliable 
information and advice with regard to evidence-based therapeutic 
modalities. 
AE management from a patient’s perspective 
Due to the variety of different AE therapies and different 
individual reactions, patients and their caregivers need clear and 
easy-to-understand strategies for their individual needs in 
therapy, and in order to become comfortable to take over 
responsibility for the treatment of their chronic condition. Patients 
and caregivers need to be trained to understand and apply the 
existing therapeutic options and best disease management 
immediately after a diagnosis of AE. Healthcare professionals 
need to be reimbursed for education, as the training of patients 
and caregivers is an imperative prerequisite for the essential 
concordance between the patient and the treating physician. Free 
access to care and medication is essential from a patient’s 
perspective. A multidisciplinary approach including 
psychological advice is needed to overcome the painful, itching 
and stigmatizing flareups and their impact on quality of life. 
Rehabilitation may play a key role. 
Patients and caregivers should be able to identify their 
individual symptoms, to become aware of the need and benefit of 
sufficient amounts of basic management (topical treatment, 
avoidance of specific and unspecific trigger factors) and to 
understand certain needs of anti-inflammatory treatment based on 
topical glucocorticosteroids (TCS) and topical calcineurin 
inhibitors (TCI). This will lead to a fast and effective short-term 
management of exacerbations, as well as long-term control by 
proactive therapy. Movement of patients and caregivers towards 
unapproved complementary alternative medicine (CAM) and 
non-compliance often result in worsening of the disease and 
should be avoided. 
Cases of severe AE should be discussed openly and in detail 
between the treating physician or multidisciplinary team and the 
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patient or caregiver, as many patients cannot overlook the 
therapeutic options, even if they have access to transparent 
guidelines. 
(a) Treatment  recommendation for atopic eczema: adult 
• For every phase, additional therapeutic options should be considered 
• Add antiseptics / antibiotics in cases of superinfection 
• Consider compliance and diagnosis, if therapy has insufficient effect 
• Refer to guideline text for restrictions, especially for treatment marked with 1 
• Licensed indication are marked with 2, off-label treatment options are marked with 3 
SEVERE: 
SCORAD >50 / or 
persistent 
eczema 
Hospitalization;  systemic 
immunosuppression:  
cyclosporine A 2, short course of oral  
glucocorticosteroids2, dupilumab 1,2 , 
methotrexate3, azathioprin 3, 
mycophenolate mofetil 3;  PUVA 1;   
alitretinoin 1,3 
MODERATE:  
SCORAD 25-50 / or 
recurrent eczema 
Proactive therapy  with topical  
tacrolimus 2 or class II or class III 
topical glucocorticosteroids 3, wet wrap 
therapy, UV therapy (UVB 311 nm,  
medium dose UVA1), psychosomatic 
counseling, climate therapy 
MILD:  
SCORAD <25 / or 
transient eczema 
Reactive therapy with topical 
glucocorticosteroids class II 2 or 
depending on local cofactors: topical 
calcineurin inhibitors 2, antiseptics incl. 
silver 2, silver coated textiles 1 
BASELINE:  
Basic therapy 
Educational programmes, emollients, 
bath oils, avoidance of clinically 
relevant allergens (encasings, if 
diagnosed by allergy tests) 
(b) Treatment recommendation for atopic eczema: children 
• For every phase, additional therapeutic options should be considered 
• Add antiseptics / antibiotics in cases of superinfection 
• Consider compliance and diagnosis, if therapy has insufficient effect 
• Refer to guideline text for restrictions, especially for treatment marked with 1 
• Licensed indication are marked with 2, off-label treatment options are marked with 3 
SEVERE: 
SCORAD >50 / or 
persistent 
eczema 
Hospitalization, systemic 
immunosuppression: cyclosporine A 3, 
methotrexate 3, azathioprin 3, 
mycophenolate mofetil 1,3 
MODERATE:  
SCORAD 25-50 / or 
recurrent eczema 
Proactive therapy  with topical  
tacrolimus 2 or class II or III topical 
glucocorticosteroids 3, wet wrap 
therapy, UV therapy (UVB 311 nm) 1, 
psychosomatic counseling, climate 
therapy 
MILD:  
SCORAD <25 / or 
transient eczema 
Reactive therapy with topical 
glucocorticosteroids class II 2 or 
depending on local cofactors: topical 
calcineurin inhibitors 2, antiseptics incl. 
silver, silver coated textiles 
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BASELINE:  
Basic therapy 
Educational programmes, emollients, 
bath oils, avoidance of clinically 
relevant allergens (encasings, if 
diagnosed by allergy tests) 
Figure 1 Treatment recommendation for adults (a) and children (b) with atopic eczema. 
 
Table 1 Grades of evidence 
1a) Meta-analysis of randomized clinical trials (RCT) 
1b) Single RCTs 
2a) Systematic review of cohort studies 
2b) Single cohort studies and RCTs of limited quality 
3a) Systematic review of case–control studies 
3b) Single case–control study 
4) Case series, case cohort studies or cohort studies of limited quality 
Recommendations (see Table 2) were classified based on the grade of evidence. 
 
Table 2 Classification of strength of recommendation 
Recommendation strength Evidence grade 
A 1a, 1b 
B 2a, 2b, 3a, 3b 
C 4 
D Expert opinion 
Patients and caregivers should actively be involved in therapeutic 
decisions at all stages to achieve therapeutic success. 
Patients with a not well-controlled AE should be informed 
about new therapeutic options and possible side-effects. 
Guidelines for patients and caregivers should be in place. 
Table 3 Language of recommendations 
General measures and avoidance strategies 
The identification of individual trigger factors is crucial in the 
management of AE, and their avoidance allows longer phases of 
remission or total clearance of symptoms. It is important to 
differentiate between the genetic predisposition towards 
hypersensitive, dry skin with barrier dysfunction – largely 
corresponding to ichthyosis vulgaris – which cannot be ‘cured’, 
and the inflammatory skin lesions which can very well be treated 
and disappear. 
In avoidance recommendations, one must distinguish between 
primary, secondary and tertiary prevention measures. Among 
provocation factors, specific and non-specific elicitors must be 
distinguished. 
Non-specific provocation factors 
Numerous factors and substances from the environment can 
irritate the sensitive skin of patients with AE and can elicit eczema 
flares. They may be physical, like mechanic irritants (e.g. wool), 
chemical (acids, bleaches, solvents, water) or biological 
(allergens, microbes) in nature. Information on unspecific 
irritants and their role in aggravating AE is a crucial prerequisite 
for long-term management of patients with AE. Here, also the 
adequate skin care and hygiene procedures in cleansing and 
dressing have to be discussed with the patient (see also 
‘Educational programme, eczema school’). 
 
Wording in standard situations Free text explanation 
Must be used This intervention should be done in all patients, unless there is a real good reason not to do it 
Should be used Most expert physicians would do it this way, but some would prefer other possible action 
May be used It would be correct to do this intervention, but it would also be correct not to do it; the choice depends largely on 
the specific situation 
Is possible Most expert physicians would do something else, but it would not be wrong to do it 
May be used in selected patients only This intervention is not adequate for most patients, but for some patients, there may be a reason to do it 
Is not recommended Most expert physicians would not choose this intervention, but some specific situation may justify its use 
Must not be used This intervention is inadequate in most situations  
Table 4 Topical drugs for treatment of atopic eczema 
 
 TCS class II TCS class III Tacrolimus Pimecrolimus 
Overall recommendation default treatment short-term flare treatment long-term maintenance children, facial lesions 
Most important side-effects Skin atrophy Skin atrophy Initial burning/stinging Initial burning/stinging 
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 Telangiectasia Telangiectasia   
 Striae distensae Striae distensae   
Suitable for long-term treatment Sometimes No Yes Yes 
Suitable for proactive therapy Yes† Yes† Yes‡ No 
Suitable for children >2 years of age Yes Sometimes, see text Yes‡ Yes‡ 
Suitable for babies <2 years of age Yes Diluted use Yes† Yes† 
Suitable during pregnancy Yes Yes Possible with strict indication† Possible with strict indication† 
Suitable during lactation Yes Yes Possible with strict indication† Possible with strict indication† 
† ‡ 
Off label use; Licensed use. 
Table 5 Upcoming topical drugs for treatment of atopic eczema 
 
 Substance Target Substance Development Registration Trial data Adverse Recommendation 
 code class phase status drug 
effect signals 
Crisaborole AN2728 Phosphodiesterase 4 PDE4 blocker IV  App. USA† More effective 
than vehicle, no 
comparative 
study 
Application site 
pain 
 OPA-15406 Phosphodiesterase 4 PDE4 blocker 
E6005 Phosphodiesterase 4 PDE4 blocker 
† 
See full text. 
PDE, phosphodiesterase; app, approved. 
Negative effects of air pollutants upon the development and 
maintenance of AE, such as tobacco smoke or volatile organic 
compounds (VOCs) in indoor environments and traffic exhaust in 
the outdoor air, must be mentioned. There is evidence from 
epidemiological trials that exposure to indoor chemicals, such as 
formaldehyde, increases skin barrier disturbance13; a mixture of 
volatile organic compounds has been shown to increase the 
intensity of atopy patch test reactions to aeroallergens in patients 
with AE.14 
Exposure to traffic exhaust has been shown to be associated 
with an increased risk to develop AE in preschool children.15,16 
Moreover, diesel exhaust particles may favour alloknesis and skin 
scratching and thus worsen AE.17 
Exposure to environmental tobacco smoke measured as urinary 
cotinin/creatinin ratio was associated with a significant elevated 
risk to develop AE which was especially pronounced in children 
of parents with an atopic background.18 The prevalence of 
smoking was higher in severe AE, as shown in a recent cross-
sectional study investigating the entire Danish population.19 A 
systematic review of 86 studies confirmed the association 
between smoking and AE in adolescents and adults in all 
continents of the earth.20 It remains unclear, however, whether 
smoking is a provocation factor in AE or whether the burden of 
AE leads to more frequent 
smoking habits.20 
Avoidance strategies regarding tobacco smoke as well as traffic 
exhaust exposure in young children have been introduced in the 
recent S3 Guideline for primary prevention of atopic diseases in 
Germany.21 
Specific allergen avoidance 
Aeroallergens Aeroallergens can elicit eczematous skin lesions in 
sensitized patients with AE, which can be explained by increased 
permeability of the skin for inhalant allergens in patients with skin 
barrier defects.22 Positive atopy patch tests are associated with 
specific IgE and positive histories of flare-ups of AE to seasonal 
allergens.23 
Many airborne allergens eliciting AE are derived from house 
dust mites (HDM) of the species Dermatophagoides 
pteronyssinus and D. farinae. The enzymatic activity of major 
mite allergens is found to destroy tight junctions of the epithelial 
cells in the bronchial mucosa and may thus also deteriorate the 
skin barrier dysfunction in patients with AE.24 
House dust mites are living in a complex ecosystem consisting 
of air humidity, temperature and presence of organic material. 
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They accompany humans and are most commonly present in dust 
from mattresses or bedroom floors. Normal cleaning measures 
help only little in decreasing house dust mite allergens present in 
settled and airborne dust indoors. Encasings of mattresses and 
beddings protect humans from house dust mites in mattresses. 
There are also mite-proof pyjamas (‘eczema overalls’). Some 
studies are showing a clear-cut benefit from house dust mite 
avoidance strategies in the improvement of AE.25,26 A recent 
meta-analysis was not in favour of house dust mite avoidance in 
established AE.27 Rehabilitation programmes in mite-free 
environments – like in alpine climate – have shown to lead to 
significant and long-lasting improvement of AE.28 
Pollen in the outdoor air also can elicit flares of AE as has been 
shown in a nested case–control study in preschool children.29 A 
challenge of sensitized patients with grass pollen in a challenge 
chamber led to exacerbation of AE in winter in a proof-of-concept 
study.30 Pollen avoidance is difficult under everyday conditions in 
most parts of Europe except when air conditioning with pollen 
filters is used in the indoor environment. In high-altitude 
mountain climate, pollen counts are usually lower than in the 
average living areas. 
Animal epithelia Many patients are aware that contact with animals 
may lead to a deterioration of skin symptoms. While in former 
times, avoidance of pets was a central feature in primary 
prevention recommendations for atopy, this has been modified as 
follows: cat epithelia exposure is regarded by most authors as a 
risk factor, so it should be avoided.31,32 There is no evidence that 
dogs increase the risk of AE in children; recent studies suggest 
that dogs might even protect from AE, possibly due to exposure 
to non-pathogenic microbes.33–35 Once a patient is sensitized to a 
pet and shows symptoms after contact, avoidance is necessary. 
Furthermore, the exposure towards bacteria is increased if dogs 
live in a household, which may have a protective effect in terms 
of primary prevention and immune regulation. However, if AE 
has developed, there may be a risk of bacterial superinfection if 
skin lesions are present and dogs have a close contact to the 
patient.36 Staphylococcus aureus, which heavily colonizes the 
lesions of AE, produces extracellular proteases, which cause 
barrier breakdown in the skin and thus facilitate the uptake of 
allergens and specific sensitization. 
Dietary recommendations 
See chapter ‘Dietary intervention’. 
Vaccinations 
It is a common misconception that AE patients and especially 
children diagnosed with AE should avoid routine vaccinations. 
There is no evidence that recommended vaccinations in infancy 
and early childhood have an impact on the development of AE or 
other atopic diseases.37 All children diagnosed with AE should be 
vaccinated according to the local or national vaccination plan. 
Vaccinations should not be administered during acute flares – in 
those cases, two weeks of well-conducted TCS therapy followed 
by a normal vaccination procedure are recommended.37 Patients 
on immunosuppressive therapy with cyclosporine or related drugs 
should consult a specialist before live vaccination is performed.37 
The only exception from this rule has been the intracutaneous 
smallpox vaccination with an attenuated live vaccine, which is 
contraindicated in AE patients due to risk of life-threatening 
eczema vaccinatum.38 A safe and effective alternative regimen 
with a highly attenuated MVA vaccine may circumvent these 
problems for AE patients in future.39 
Clothing and textiles – contact allergens 
Smooth clothing and avoidance of irritating fabrics and fibres are 
essential in the avoidance of primary skin irritation. Silk garments 
with an AEGIS-coating are lightweight and comfortable to wear, 
but do not improve eczema severity over standard of care 
treatment.40 Too occlusive clothing inducing heat sensations 
should be avoided. 
Obviously, contact allergens relevant to the patient should also 
be avoided. This is of special relevance if type IV allergy to 
ingredients of emollients has been diagnosed by classical patch 
tests. Emulsifiers, fragrances and preservatives are the main 
causes of contact allergy to cosmetics.41 
Occupational aspects 
Special recommendations must be given in individual counselling 
programmes regarding the choice of profession. There is common 
consensus that occupations involving contact with strongly 
sensitizing substances should be avoided by patients with AE.42 
Professions with skin irritating tasks are not recommended to 
atopic individuals with a history of persistent or relapsing hand 
eczema. The risk of contact sensitization is slightly increased in 
patients with AE.43 
Summary of evidence 
There is some evidence that house dust mite avoidance strategies, 
especially encasings, can reduce house dust mite and house dust 
allergen content in indoor air and therefore improve AE. The 
latter is controversial, as a recent meta-analysis would not 
confirm this effect. (2b). 
There is evidence that house dust mite avoidance and 
highaltitude climate may give benefit to patients suffering from 
AE. (2b, 3b). 
There is a rationale for using protective clothes (eczema 
overalls), although good studies are missing. (-). In spring and 
666 Wollenberg et al. 
 
summertime, pollen exposure may exacerbate AE in the air-
exposed skin areas. (-). 
Vaccination does neither improve nor worsen the natural 
course of AE. (2a). 
Recommendations 
• Pollen avoidance measures can be recommended during 
the pollen season. (-, D) 
• House dust mite avoidance measures may be tried in 
selected cases. (-, D) 
• When classical patch tests are positive, relevant contact 
allergens should be avoided. (-, D) 
• All children diagnosed with AE should be vaccinated 
according to the national vaccination plan. (2a, B) 
Basic therapy of disturbed skin barrier function and 
emollient therapy (‘skin care’) 
Emollient therapy and skin care 
Dry skin is one of the characteristic symptoms of AE. There is 
now scientific evidence in humans and mice of genetically driven 
skin barrier anomalies that facilitate allergen penetration into the 
skin with an increased proneness to irritation and subsequent 
cutaneous inflammation. Filaggrin deficiency is the bestdefined 
anomaly, which gives rise to a deficiency in small waterbinding 
molecules resulting from normal filaggrin catabolism.44 Besides 
that, a lack of stratum corneum intercellular lipids and an 
inadequate ratio between compounds (cholesterol, essential fatty 
acids, ceramides) enhance transepidermal water loss leading to 
epidermal microfissuring. Barrier disruption leads to 
inflammation, and protease–antiprotease imbalance is a crucial 
intermediate step.45 
Cleansing and bathing 
The skin must be cleansed thoroughly, but gently and carefully, 
to get rid of crusts and mechanically eliminate bacterial 
contaminants in the case of bacterial superinfection. Cleansers 
with or without antiseptics (the duration of action of antiseptics is 
very limited; thus, mechanical cleansing is probably more 
important) in non-irritant and low-allergen formulas available in 
various galenic forms (syndets, aqueous solutions) may be used. 
It is easier to perform this first stage of gentle cleansing of skin 
on the nappy mattress rather than directly in the bathtub in 
infants.3 A further cleansing followed by a rapid rinse is 
performed in the bath (27–30°C). The short duration of the bath 
(only 5 min) and the use of bath oils (2 last minutes of bathing) 
are aimed at avoiding epidermal dehydration. Topical emollients 
are preferentially applied directly after a bath or a shower 
following gentle drying when the skin is still slightly humid (see 
next section on emollient therapy). 
Adding antiseptics such as sodium hypochlorite to the 
bathwater is an additional option for the treatment of AE because 
of its bacterial count inhibiting activities.46,47 A study showed that 
children bathing in 0.005% bleach experienced an improvement 
of their AE.47,48 In a recent study, sodium hypochlorite baths did 
not show superiority to water baths concerning the severity of AE, 
but allowed a reduction in topical corticosteroid and antibiotic 
usage.49 Salt baths may be beneficial because of removing the 
dead keratin material.50 Salt baths are useful especially in heavily 
impetiginized or ichthyotic skin. A recent study suggested the 
usage of fragrance-free baby oil as a soap substitute, especially in 
populations where specially designed emollients are not 
affordable.51 
Bath oils are a valuable addition for skin care especially in 
babies and children. Bath additives containing potentially 
allergenic proteins such as from peanut or colloidal oat should be 
avoided in the most vulnerable age group before the age of two.3 
It should be emphasized that most bath oils commercially 
available in Europe are practically free of these protein allergens. 
Recommendations 
• Adding antiseptics such as sodium hypochlorite to the 
bathwater may be useful for the treatment of AE (1b, A). 
Emollient therapy 
By tradition, emollients are defined as topical treatment with 
vehicle-type substances lacking active ingredients. These 
emollients are extremely helpful for AE patients and contain 
usually a humectant (promoting stratum corneum hydration, such 
as urea or glycerol) and an occludent (reducing evaporation, such 
as petrolatum). Recently, marketing of non-medicated 
‘emollients’ containing active ingredients has softened the 
delineation of emollients from topical drugs. Throughout this 
guideline, ‘emollients’ are defined as ‘topical formulations with 
vehicle-type substances lacking active ingredients’, whereas 
‘emollients plus’ refers to ‘topical formulations with vehicle-type 
substances and additional active, non-medicated substances’. 
The direct sole use of emollients on inflamed skin is poorly 
tolerated, and it is better to treat the acute flare first. Emollients 
are the mainstay of management. Hydration of the skin is usually 
maintained by at least twice daily application of moisturizers with 
a hydrophilic base, e.g. 5% urea.52 According to the acuity of the 
skin condition, lipophilic bases are also helpful. The use of barrier 
ointments, bath oil, shower gel, emulsions or micellar solutions 
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enhancing the barrier effect is also recommended. The cost of 
high-quality (low in contact allergens) emollient therapies often 
restricts their use because such therapies are considered to be non-
prescription drugs (except for, e.g., Finland and Switzerland, 
where prescription and reimbursement are usual), and the 
quantities required are usually high (up to 100 g per week in 
young children, and up to even 500 g in adults). The use of pure 
oil products such as coconut oil instead of emulsions will dry out 
the skin, increases the transepidermal water loss and is therefore 
not recommended. 
The applied amount of topicals may also follow the fingertip 
unit rule: A fingertip unit (FTU) is the amount of ointment 
expressed from a tube with a 5-mm-diameter nozzle and measured 
from the distal skin crease to the tip of the index finger (~0.5 g); 
this is an adequate amount for application to two adult palm areas, 
which is approximately 2% of an adult body surface 
area.53 
A better molecular and biochemical knowledge of the skin in 
AE should provide access to barrier improving topical agents. 
There is increasing evidence-based proof for the use of emol- 
lients.54 
Ingredients and possible risks of emollients 
Urea may cause irritation and kidney dysfunction in infants and 
should be avoided in this age group, whereas toddlers should be 
treated with lower concentrations than adults.3 Glycerol seems 
better tolerated (less smarting effect) than urea plus sodium 
chloride.55 Usually, the recommendation is to use emollients 
immediately after bathing and soft pad drying. A small study 
suggests that an emollient applied alone without bathing may 
have a longer duration as measured by 
capacitance.56 
Propylene glycol is easily irritating in young children aged less 
than two years and should not be used for toxicity reasons in these 
young children. There is concern that the large preventive use of 
emollients containing intact proteins such as peanut allergens 57 
or colloidal oat meal 58 may increase the risk of skin sensitization 
and allergy. Only emollient preparations devoid of proteinaceous 
allergens and haptens known to cause contact allergy frequently 
(such as lanolin/ wool wax alcohol or methylisothiazolinone) 
should be used, especially in the most vulnerable age group before 
the age of two years. 
Emollients containing tannin- and ammonium 
bituminosulphonate (ichthammol) may be a useful addition to the 
basic treatment regimen, especially in mild disease or if TCS 
treatment is not possible from a patient’s perspective, e.g. 
corticophobia (steroid phobia).59 
Sole use of emollients without sufficient topical anti-
inflammatory therapy involves a considerable risk of 
disseminated bacterial and viral infection of AE, which is already 
increased in AE patients.60 
Emollients ‘plus’ 
In the last years, several non-medicated products for topical 
treatment of AE are available on the market, which contain active 
ingredients, but are neither fulfilling the definition of nor needing 
a licence as a topical drug. These products may contain, for 
example, saponins, flavonoids and riboflavins from proteinfree 
oat plantlet extracts, or bacterial lysates from Aquaphilus 
dolomiae or Vitreoscilla filiformis.61 These lysates both improve 
AE lesions and influence the skin microbiome of AE patients.62,63 
In vitro and clinical research data from different laboratories have 
provided some background information on molecular targets and 
possible mode of action of these active emollients ‘plus’.64–66 
Evidence of emollient efficacy 
Certain moisturizers could improve skin barrier function in AE 
and reduce skin susceptibility to irritants. It was clearly 
demonstrated that long-term emollient therapy improves 
AEassociated xerosis.67 Simple stand-alone emollient application 
for one week may improve mild-to-moderate AE.68 A 
comparative study showed that an over-the-counter moisturizer 
could be as clinically effective as more expensive barrier creams 
in the management of mild-to-moderate childhood AE.69 Another 
study in adult AE patients suggested an effect of coconut oil on 
staphylococcus aureus carriage.70 In addition, the daily use of 
emollients from birth may significantly reduce the incidence of 
AE in a high-risk population.71,72 As the major limitation of these 
two promising trials is their relatively short duration of half a 
year, longer trials are currently performed. 
Evidence of steroid sparing effects of emollients 
Short term (3–6 weeks) Several studies in children54,73 and one in a 
mixed children–adult population74 showed a variable but 
consistent evidence of short-term steroid sparing effect in mildto-
moderate AE. 
Long-term maintenance therapy Maintenance of stable disease can 
be obtained with emollients used twice weekly or more frequently 
in a subset of patients, after an induction of remission with topical 
corticosteroids. Several studies showed comparable results for 
intermittent emollient therapy and time to relapse, using 
comparable study designs in adults and 
children.75,76 
668 Wollenberg et al. 
 
Recommendations 
• Emollients should be prescribed in adequate amounts, 
and these should be used liberally and frequently, in a 
minimum amount of 250 g per week for adults (3b,C). 
• Emollient bath oils and soap substitutes should also be 
used. Emollients with a higher lipid content are 
preferable in wintertime (3b,C). 
• A regular use of emollient has a short- and long-term 
steroid sparing effect in mild-to-moderate AE. An 
induction of remission with topical corticosteroids or 
topical calcineurin inhibitors is required first (2a,B). 
Dietary intervention 
Food allergens, pre- and probiotics 
Food allergy has been well documented in approximately one-
third of children with moderate–severe AE.77 Among food 
allergens, cow’s milk, hen’s egg, peanut, soya, nuts and fish are 
most frequently responsible for AE exacerbation in young 
children, with age-dependent variations in causally incriminated 
food.78 In older children, adolescents and adults pollen-associated 
food allergy should be taken 
into account.79,80 
Response patterns to food allergens 
Three different clinical reaction patterns in patients with AE have 
been described, depending on the type of symptoms and 
their time of onset.78,81 
Immediate-type, non-eczematous reactions are usually 
IgEmediated, occur within 2 h after the administration of the 
allergen, with skin manifestations such as urticaria, angio-
oedema, flush, and pruritus or other immediate-type reactions of 
the gastrointestinal tract, the respiratory tract or the 
cardiovascular system in the sense of anaphylaxis. Cutaneous 
manifestations occur in 74% of patients. In addition, children 
might develop a transient morbilliform rash 6–10 h after the initial 
immediate reaction, disappearing within a few hours and 
considered as ‘latephase’ IgE-mediated response.81,82 
Isolated eczematous delayed-type reactions typically occur 6– 
48 h after the administration of the allergen with flares of eczema 
on predilection sites of AE, suggestive for a nonanaphylactic 
pattern. 
A combination of the two above-mentioned patterns with an 
immediate-type reaction followed by an eczematous delayedtype 
reaction has been described in approximately 40% of 
children.83 
Sensitization to food can be identified by means of a detailed 
clinical history in combination with in vivo tests (skin prick tests, 
prick–prick tests) and in vitro tests (serum-specific IgE). In 
addition, patch tests proved to be useful for studying delayed 
food-related skin responses. In vitro tests are valuable when skin 
prick tests (SPT) cannot be applied (e.g. dermographism or UV- 
and drug-induced skin hyporeactivity, eczema at the test site, lack 
of compliance for SPT in infancy). Moreover, in vitro specific IgE 
to food allergens gives better quantitative data for the grade of 
sensitization which helps to estimate the probability of the risk of 
a clinical reaction (although precise decision points are not 
available) and it offers the opportunity to test single recombinant 
allergens which may have a better diagnostic specificity than 
testing with food extracts for some foods (e.g. omega-5-gliadin in 
wheat allergy, Gly m 4 in pollen-related soya allergy). 
Atopy patch test (APT) is performed with self-made food 
material using a 1/10 dilution in saline of the fresh food applied 
for 24–48 h on non-lesional skin.84 Food APT is not standardized 
for routine use. So far, APTs have demonstrated to improve the 
accuracy of skin testing in the diagnosis of allergy to cow’s milk, 
eggs, cereals and peanuts in patients with AE.85–88 Whereas 
immediate-type reactions are associated with SPT positivity, 
delayed reactions are related to positive responses to APTs. 
However, double-blind placebo-controlled food challenge 
(DBPCFC) remains the ‘gold standard’ for the diagnosis of FA.89 
Oral food challenge (OFC) should always be performed under 
medical supervision with emergency equipment available, 
particularly after long-lasting elimination of the culprit food. 
Practically, OFC should be performed according to standardized 
protocols considering variables associated with food matrix, 
doses and time intervals.90 In AE, the major flaw is that DBPCFC 
might not offer the opportunity to exclude placebo reactions or 
coincidental influences of other trigger factors of AE during the 
prolonged challenge period. Therefore, in AE, the evaluation of 
delayed reactions after 24 h or 48 h by trained personal is 
mandatory.83 Challenge tests based on repeated exposure to food 
enable the assessment of delayed adverse responses.83 
Unfortunately, the effects of dietary interventions on the course 
of AE have been studied only in a few controlled studies. In a 
systematic review,11 eight randomized controlled studies 
examining the effect of an elimination diet on existing AE were 
identified and summarized in the following way: a) elimination 
diets are difficult to carry out even in a motivating atmosphere 
during a clinical study. b) The dropout rate in AE studies is 
particularly high in studies on diets. c) There is no convincing 
evidence that a milk- or egg-free elimination diet is beneficial in 
general, when unselected groups of patients with AE were 
studied. d) There is no evidence for a benefit in the use of 
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elementary or few food-restricted diets in unselected patients with 
AE. 
A Cochrane systematic review based on nine randomized 
controlled trials concluded that eliminating egg from the diet in 
those who had positive specific IgE to eggs proved beneficial.91 
The American Academy of Dermatology recommended egg 
restriction in the subset of patients with AE who were found to be 
clinically allergic to eggs,92 but this approach should also be 
followed for other food allergens proven relevant in individual 
patients. 
Although progress has been considerable, there are no simple 
strategies to prevent the development of AE and food allergy in 
infants. The recent publication of randomized trials, such as the 
Learning Early About Peanut Allergy (LEAP) 93 and Enquiring 
About Tolerance (EAT) 94 studies, has given some support to the 
notion that early oral ingestion of food may protect from 
sensitization and allergy later in life. The oral introduction early 
in the first year of life at a ‘window of opportunity’ of time 
between 4 and 6 months of age may actually protect children by 
facilitating the induction of tolerance.95 Epidemiological studies 
have shown a significant association between the diversity of 
foods given in the first year of life and protection form atopic 
eczema.96 
Pre- and probiotics 
Probiotics such as lactobacillus mixtures have been studied in AE 
and have been shown to induce improvement.97 Other studies 
failed to show significant effects.98,99 In a study with 800 infants, 
the effect of a prebiotic mixture was investigated and found to 
have beneficial effects in preventing the development of AE.100 
Non-pathogenic bacterial strains such as Vitreoscilla filiformis 
or Aquaphilus dolomiae have been used as sources for bacterial 
lysates for topical therapy of AE (see chapter ‘Topical therapy’). 
Previous systematic reviews on probiotics for the treatment of 
AE have consistently concluded a lack of effect in children.101 On 
the basis of the existing literature, with only one group showing 
positive results in a controlled study, the guideline group decided 
not to give a recommendation for treatment with lactobacilli in 
AE. It may well be that a preventive effect of preor probiotic 
mixtures will be shown in future; consultation of the S3 guideline 
on ‘prevention on allergy’ is recommended.21 
Summary of evidence 
Food sensitization occurs in about 50% of children with severe 
AE. The relevance can be evaluated by oral provocation tests, best 
performed as double-blind placebo-controlled food challenge. 
(1a) 
Food allergy plays a role for disease exacerbation in 30% of 
AE children, most often against basic foods such as hen’s egg or 
cow’s milk. Pollen-associated food allergy can occur in all ages. 
(2a) 
Food elimination diets represent a major impairment in quality 
of life and are not easy to perform. (2a) 
There is evidence that elimination of basic foods in food 
allergic children can improve the AE. (1a) 
The persistence of food allergy can be evaluated by oral 
provocation after 1 or 2 years. (3a) 
There are no long-term studies to the effect of food elimination 
diets in AE. (-) 
There is conflicting data on prevention or improvement of AE 
during uptake of probiotics such as lactobacillus preparations. 
(1b) 
Recommendations 
• Patients with moderate-to-severe AE should observe a 
therapeutic diet eliminating those foods that elicitated 
clinical early or late reactions upon controlled oral 
provocation tests. (2b, B) 
• Primary prevention of food allergy-associated AE is 
recommended with exclusive breast milk feeding until 4 
months of age. (2–3, C) 
• If breast milk is lacking in low-risk children (general 
population), conventional cow’s milk formula is 
recommended. (2–3, C) 
• If breast milk is lacking in high-risk children (one-first 
degree relative to physician diagnosed allergic 
symptoms), a documented hypoallergenic formula is 
recommended. (1, B) 
• Introduction of complementary foods is recommended 
between 4 and 6 months of age in low- and high-risk 
children irrespective of an atopic heredity. (1–2, B) 
• A certain diversity of foods selected should be observed 
during the introduction between 4 and 6 months of age. 
(1, D) 
Topical anti-inflammatory therapy 
Topical treatment: overall principles 
Effective topical therapy depends on three fundamental 
principles: sufficient strength, sufficient dosage and correct 
application.3 Many formulations are available especially for 
corticosteroids, and the choice of formulation has a strong impact 
on the efficacy of the resulting drug. Topical treatment should 
always be applied on hydrated skin, especially when using 
ointments. Patients with acute, oozing and erosive lesions and 
children sometimes do not tolerate standard topical application 
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and may first be treated with ‘wet wraps’ until the oozing stops. 
Wet-wrap medications are highly effective in acute AE and 
improve tolerance. The use of wet-wrap dressings with diluted 
corticosteroids for up to 14 days (usual is rather up to 3 days) may 
be a safe crisis intervention treatment of severe and/or refractory 
AE with temporary systemic bioactivity of the corticosteroids as 
the only reported serious side-effects.102–105 However, this 
treatment approach is not standardized yet, and the evidence that 
it is more effective than conventional treatment with topical 
steroids in AE is not of high quality. Simple or occlusive 
medications in less sensitive skin areas and for brief time periods 
may also increase efficacy and speed up lesion resolution. Even 
without wet wraps, topical therapy may be time-consuming and 
deserves attention. One well-conducted treatment per day is 
usually sufficient, but acute flares may require a few days with 
higher treatment frequency. 
By tradition, anti-inflammatory topical therapy has been 
administered to lesional skin only and has been stopped or tapered 
down once visible lesions were cleared. This traditional, reactive 
approach has now an alternative, which is the proactive treatment 
concept. Proactive therapy is defined as a combination of 
predefined, long-term, anti-inflammatory treatment applied 
usually twice a week to previously affected areas of skin in 
combination with liberal use of emollients on the entire body and 
a predefined appointment schedule for clinical examinations.106 
The proactive regimen is started after all lesions have successfully 
been treated by a regular anti-inflammatory therapy (by either 
steroids or topical calcineurin inhibitors) in addition to ongoing 
emollient application on previously unaffected skin. Clinical trial 
data are available for a number of steroid products as well as for 
tacrolimus ointment,107 but topical steroids are usually approved 
only for a very limited period of time such as a few weeks. Studies 
investigating topical steroids for proactive treatment are usually 
conducted only for 16 weeks, whereas studies with tacrolimus 
ointment have shown good results for 52 weeks in both children 
and adults. The duration of the proactive management is usually 
adapted to the severity and persistence of the disease.108 The 
applied amount of anti-inflammatory topicals should also follow 
the fingertip unit rule (see chapter ‘Emollient therapy’). 
Glucocorticosteroids 
Topical glucocorticosteroids (TCS) are a first-line anti-
inflammatory treatment, applied on inflammatory skin according 
to the needs (pruritus, sleeplessness, new flare). Numerous 
substances are available in a variety of formulations. 
Antiinflammatory effects in AE were reported by different 
investigators.109,110 With mild disease activity, a small amount of 
topical corticosteroid twice to thrice weekly (monthly amounts in 
the mean range of 15 g in infants, 30 g in children and up to 60– 
90 g in adolescents and adults, roughly adapted to affected body 
surface area) associated with a liberal use of emollients generally 
allows a good maintenance. Such monthly amounts of even potent 
topical steroids usually do not have adverse systemic or local 
effects. Twice-weekly application of fluticasone or 
methylprednisolone aceponate significantly reduced the risk of 
relapses of AE in a proactive strategy.109–112 
Several factors should be considered when choosing a topical 
corticosteroid, including potency, galenic formulation, patient age 
and body area to which the medication will be applied. The 
potency of topical corticosteroids is grouped by potency 
according to Niedner from mild (group I) to superpotent (group 
IV).113 Prescribers should know this classification, as they should 
know that the US-American classification is different and ranges 
from VII (weakest) to I (strongest). In France, this classification 
is even different. Superpotent TCS (group IV) are not 
recommended for AE treatment, especially not in children.3 
Potent and very potent corticosteroids of groups III and IV are 
more likely to cause depression of adrenal function than group I 
and group II treatments, but their systemic effects will decrease 
more quickly due to more rapid restitution of the skin barrier.114 
Treatment of the face and especially the eyelid region should be 
restricted to mild TCS (group I and II). Children should be treated 
with less potent TCS than adults. In addition, there are different 
generations of substances, which may differ in their risk/ benefit 
ratio. 
Itch is the key symptom for evaluation of response to treatment, 
and tapering should not be initiated before the itch has largely 
improved. Two applications per day may be necessary to reduce 
the itch, but one well-conducted, correctly dosed treatment per 
day may be sufficient.115,116 Dose tapering is usually applied to 
avoid withdrawal rebound, although no controlled studies have 
demonstrated its usefulness. Tapering strategies consist of 
switching to a less potent corticosteroid, or keeping a more potent 
one while reducing the frequency of application (intermittent 
regimen). The most constructive way to spare steroids and avoid 
steroid-related side-effects is to use them intensively during the 
acute flares.3 Continuous emollient skin care combined with early 
anti-inflammatory intervention is also very important to stabilize 
the disease and prevent 
flares.117 
Side-effects of topical corticosteroids comprise a variety of 
skin changes mostly in the sense of skin atrophy – except from 
contact allergy to glucocorticosteroid substances. The skin 
changes manifest as thinning of the skin, development of 
telangiectasias (rubeosis steroidica), spontaneous scars 
(‘pseudocicatrices stellaires’), ecchymosis, striae distensae 
(stretch marks), a ‘dirty neck’ (cutis punctata linearis colli) and 
hypertrichosis may develop. In infants, inappropriate use of TCS 
in the diaper area can lead to granuloma gluteale infantum or even 
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iatrogenic Cushing’s disease. The risk of ocular complications by 
topical corticosteroids seems to be low. Development of 
glaucoma or cataract has been described after systemic 
glucocorticosteroid applica- 
tion.118 
The use of potent topical corticosteroids in sensitive skin areas 
(face, neck, folds) should be limited in time to avoid skin 
atrophy.119 Monitoring by physical examination for cutaneous 
side-effects during long-term use of potent topical corticosteroids 
is very important. The special aspects and potential adverse 
effects of topical corticosteroids in pregnancy have been recently 
reviewed.120 The application of topical corticosteroids to the 
eyelids and periorbital region even over longer periods of time in 
adults with AE was not associated with the development of 
glaucoma or cataracts.118 Application of very potent topical 
corticosteroids even for brief time periods may result in the drug 
becoming systemically available and potent enough to induce 
adrenal gland suppression.121 
In the face, a special skin condition called rosacea-like perioral 
dermatitis is often started by inappropriate, long-term use of TCS. 
The skin seems to become ‘addicted’ to TCS (‘red face syndrome’ 
or ‘corticosteroid addiction syndrome’). This is characterized by 
rosacea-like disease with persistent erythema, burning and 
stinging sensation. It has been reported mostly on the face and 
genital area of women primarily in the setting of long-term 
inappropriate use of potent topical corticos- 
teroids.122 
Patient fear of side-effects of corticosteroids (corticophobia) is 
quite common and should be recognized and adequately 
addressed to improve adherence and avoid undertreatment.123– 
125 
The simultaneous combination of topical corticosteroids with 
topical calcineurin inhibitors at the same site does not seem to be 
useful. At least in paediatric patients with severe AE, the efficacy 
and safety profile of pimecrolimus cream 1% combined with 
fluticasone were similar to those of fluticasone alone.126 Treating 
sensitive body areas such as the face with topical calcineurin 
inhibitors while treating other affected body areas with a topical 
corticosteroid may be a useful and cost-effective strategy. Initial 
treatment with topical corticosteroids may be considered in 
patients with acute flare to minimize topical calcineurin inhibitor 
site reactions.108 
Summary of evidence 
Topical corticosteroids have a significant effect improving skin 
lesions compared to vehicle. (1b) 
The efficacy of topical glucocorticosteroids can be increased 
using wet wraps. (1b) 
Recommendations 
• Topical corticosteroids are important anti-inflammatory 
drugs to be used in AE, especially in the acute phase. (-, 
D) 
• Topical corticosteroids with an improved risk/benefit 
ratio are recommended in AE. (-, D) 
• Diluted topical corticosteroids may be used under wet 
wraps for short-term periods in acute AE to increase their 
efficacy. (1b, A) 
• Proactive therapy, e.g. twice-weekly application in the 
long-term follow-up, may help to reduce relapses. (1b, 
A) 
• Proactive therapy with TCS may be used safely for at 
least 20 weeks, which is the longest duration of trials (1b, 
A). 
• Patient fear of side-effects of corticosteroids 
(corticophobia) should be recognized and adequately 
addressed to improve adherence and avoid 
undertreatment. (4C) 
Topical calcineurin inhibitors 
Two topical calcineurin inhibitors (TCI), tacrolimus ointment and 
pimecrolimus cream, are licensed for AE treatment. The efficacy 
of both formulations has been demonstrated against vehicle in 
clinical trials for short-term127,128 and long-term use.129,130 In 
addition, proactive tacrolimus ointment therapy has been shown 
to be safe and effective for up to 1 year in reducing the number of 
flares and improving the quality of life in both adults and 
children.131,132 The anti-inflammatory potency of 0.1% tacrolimus 
ointment is similar to a corticosteroid with intermediate 
potency,133,134 whereas the latter is clearly more effective than 
1.0% pimecrolimus cream.135 
The efficacy of long-term monotherapy with tacrolimus 
ointment has been shown in children and adults.133,134,136 Less data 
are available for children under 2 years of age.137,138 Pimecrolimus 
cream has been studied in infants and children in a combination 
regimen with topical corticosteroids,139,140 the latter being given if 
a flare occurred. Both topical calcineurin inhibitors are approved 
in the EU from 2 years of age and above. High-quality long-term 
safety data have recently been published on a 4-year tacrolimus 
study and a 5-year pimecrolimus study.141,142 The cost-
effectiveness of proactive therapy with tacrolimus has been 
demonstrated for moderate AE and is even higher in severe AE in 
a recent study on adult patients,143 whereas the cost-effectiveness 
of first-line treatment with topical calcineurin inhibitors has not 
been demonstrated conclusively. However, in children with AE, 
twice-weekly treatment with tacrolimus 0.03% ointment has been 
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observed to reduce the number of flares and to prolong flare-free 
intervals and may be cost-saving in children with moderate or 
severe 
AE.144,145 
In addition, the long-term, effective treatment of patients with 
AE may have a beneficial effect also on respiratory symptoms and 
serum IgE.146 In adults, long-term treatment with 0.1% tacrolimus 
ointment appears to be at least as effective as a corticosteroid 
regimen for the trunk and extremities and more effective in the 
face and neck area. Both topical tacrolimus and corticosteroids 
decrease skin recall activity and decrease serum IgE in patients 
with treatment response. 
Safety data of both topical calcineurin inhibitors have been 
reported in many clinical trials and registries, demonstrating the 
safety of these drugs in daily routine use. The most frequently 
observed side-effect is a transient warmth, tingling or burning 
sensation at the application site during the first days of 
application.127,135 It starts about 5 min after each application of the 
drug and may last up to 1 h, but intensity and duration typically 
disappear within few days.147 Some patients experience a transient 
worsening of skin conditions. These side-effects are more 
common with tacrolimus ointment than with pimecrolimus cream 
and when they are applied on acutely inflamed skin. In some 
patients, they are severe enough to induce prompt treatment 
discontinuation. Initial treatment with topical corticosteroids 
should thus be considered in patients with acute flare to minimize 
these site 
reactions.108 
Generalized viral infections such as eczema herpeticum or 
eczema molluscatum have been observed during topical 
calcineurin inhibitor treatment,148,149 but a high number of clinical 
trials failed to demonstrate an increased frequency or showed only 
a transient increase (reviewed in150–153). In contrast to 
corticosteroids, none of the topical calcineurin inhibitors induces 
skin atrophy.154,155 This favours their use over topical 
corticosteroids in delicate body areas such as the eyelid region, 
the perioral skin, the genital area, the axilla region or the inguinal 
fold and for topical long-term management. Clinical and 
preclinical data do not indicate an increased risk of lymphoma.156 
In contrast, severe AE as such may carry an independent 
significant risk of lymphoma.156 The use of topical calcineurin 
inhibitors is also not associated with increased risk of non-
melanoma skin cancer, other malignancies or 
photocarcinogenicity.142,157–161 However, given that the longterm 
use of cyclosporine is associated with an increased 
photocarcinogenicity risk in solid organ transplant patients, UV 
protection, e.g., with sunscreens has been advised.3 The use of 
topical calcineurin inhibitors under wet wraps or on erosive 
lesions may increase systemic absorption. 
Clinicians should be aware of the black-box warning on the use 
of topical calcineurin inhibitors and may discuss this with patients 
to improve adherence. 
Summary of evidence 
Topical calcineurin inhibitors have a significant effect compared 
to vehicle in short-term and long-term treatment of AE. (1b) 
Tacrolimus 0.1% ointment is more potent than pimecrolimus 
cream. (1b) 
Tacrolimus ointment and to lesser extent pimecrolimus cream 
may cause burning sensation and transiently worsen AE 
especially when given on acutely inflamed skin. (1a) 
Topical calcineurin inhibitors do not cause skin atrophy, 
glaucoma or cataract. (1a) 
Recommendations 
• Topical calcineurin inhibitors (TCI) are important anti-
inflammatory drugs to be used in AE. (-, D) 
• Instead of treating acute flares with TCI, initial treatment 
with topical corticosteroids before switching to TCI should 
be considered. (-, D) 
• TCI are especially indicated in sensitive skin areas (face, 
intertriginous sites, anogenital area). (1b, A) 
• Proactive therapy with twice-weekly application of 
tacrolimus ointment may reduce relapses. (1b, A) 
• Effective sun protection should be recommended in 
patients treated with TCI. (-, D) 
Upcoming topical therapies 
Topical selective phosphodiesterase 4 inhibitors Crisaborole is a 
topical phosphodiesterase 4 inhibitor effective in the treatment of 
AE lesions, which has recently been approved for the treatment 
of mild-to-moderate AE in patients 2 years of age and older in the 
United States of America.162,163 Study data published have 
focused on treatment of individual skin lesions using global 
eczema scores, as well as on safety aspects, but do not include 
SCORAD data or EASI data of the patients treated. From the 
published data of the global scores and the individual items of an 
eczema score, a relatively low efficacy of crisaborole is 
probable.162 The efficacy of crisaborole is significantly higher 
than the efficacy of its vehicle. However, the efficacy of 
crisaborole in comparison with TCI or TCS is difficult to 
determine. Crisaborole ointment is currently not licensed in 
Europe. 
Other topical phosphodiesterase 4 inhibitors under 
investigation include OPA-15406 and E6005.164,165 
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Topical Janus kinase (JAK) inhibitors First promising phase II 
clinical trial data with the topical JAK inhibitor tofacitinib have 
been published,166 but the topical development programme was 
halted. Further similar compounds are in the pipeline for topical 
as well as for systemic therapy, but none is currently licensed in 
Europe. 
Phototherapy 
As most patients affected by AE improve during the sunny 
summer season, artificial UV radiation is frequently employed in 
the treatment of AE. On the contrary, a small group of patients 
will exacerbate following UV radiation. 
A recent study has confirmed that 74% of patients affected by 
mild–moderate AE had complete resolution during summer 
holidays, 16% had improvement and only 9% had no modification 
of AE severity, confirming the seasonality of the disease, with 
improvement during summertime and worsening in the other 
seasons: seaside holidays produced a significantly greater 
improvement than mountains holidays, with complete resolution 
of the disease in 91% vs. 11% of patients (P < 0.01).167 While this 
difference cannot be explained on the sole basis of UV exposure, 
these data support the hypothesis on the positive effect of UV 
radiation on AE. 
Photobiology of AE treatment 
Various pathways and means through which the energy of UV 
radiation from natural or artificial sources is ultimately 
transformed into biologic effects within the skin have been 
suggested, including cutaneous sensory nerves, neuropeptides, 
neurotrophins and certain nerve-related receptors.168 In general, 
the effects of UV light sources on the skin act 
immunosuppressive, immunomodulating and anti-inflammatory 
as well as antipruritic, which is obviously an overlapping effect. 
The known mechanisms of action target immunomodulation 
through apoptosis of inflammatory cells, inhibition of Langerhans 
cells and alteration of cytokine production.169 In addition, UV has 
an antimicrobial effect reducing the colonization of S. aureus,170 
due to its antiinflammatory effect and improves skin barrier.171 A 
different explanation could be supported by the role of Vitamin 
D: a recent study demonstrated that a 2-week course of 
heliotherapy significantly improved vitamin D balance by 
increasing serum calcidiol concentration and caused a marked 
healing of AE.172 Suppression of Th2-associated cytokines such 
as IL-5, IL-13 and IL-31 has been observed under UVA1 
therapy.169 Induction of apoptosis of T helper cells most probably 
is related to generation of reactive oxygen species (ROS).173,174 
Depletion and loss of function of antigen-presenting cells within 
the epidermis and dermis support immunosuppression via UV 
light source. Reduction in ICAM1 expression on keratinocytes 
has been observed and further enhanced via IL-10-induced 
reduction in c-IFN.175,176 
Light sources and current treatment regimen for AE Heliotherapy 
uses the exposure to natural sun light under controlled conditions 
and is part of the therapeutic treatment in socalled climate therapy 
at low altitude (Dead Sea) predominantly with UVA,177 at sea 
level or at high altitude (e.g. Davos) with predominantly UVB.178 
The dose in heliotherapy is slowly increased by increasing the 
time of sun exposure in moderate increments. 
The following alternative modalities of UV treatment have 
been used in AE: UVB (mostly narrowband (NB-UVB) of 311– 
313 nm and less frequently broadband (BB-UVB)), UVA 
(especially UVA1 of 340–400 nm), combined UVAB and 
photochemotherapy where UV can be combined with previous 
oral or topical administration of photosensitizing drugs such as 
psoralens – the PUVA photochemotherapy regimen, but the 
longterm risks of skin cancer noted in psoriasis have drastically 
limited this modality in Europe. In contrast, classical broad-
spectrum UVB phototherapy does not show increased risk of 
BCC and SCC.179,180 
Other light therapies have been introduced. Short-wave visible 
light (> 380 nm) (‘blue light’) may have some effects, as indicated 
in uncontrolled pilot studies.181 There are no controlled studies for 
this modality. Photopheresis is used in some centres for the 
treatment of selected cases. Positive effects in patients with severe 
refractory AE have been described. Other devices such as 308-nm 
monochromatic excimer laser expand the therapeutic options in 
patients with localized and therapyresistant AE even though they 
can treat only limited surfaces.182,183 Pulsed-dye laser for the 
treatment of chronic AE is still experimental.184 
Currently, the mainstay for phototherapy in Europe is NBUVB 
and UVA1. Following concerns relative to PUVA, longterm risks 
of UV light therapies have to be considered in particular in 
children and even more in adults who have received systemic 
immunosuppressants. Until now, no clinical studies have shown 
an increase in non-melanoma skin cancer with NB-UVB and 
UVA1.185,186 The benefit/risk ratio of medium- and highdose 
UVA1 (>20–70 J/cm2) is considered as better than that of high or 
low dose.187–190 Comparison of middle–high UVA1 and NB-UVB 
does not show significant differences with regard to efficacy and 
tolerability. 
Taking into account the individual tolerability, NB-UVB has 
been indicated for chronic moderate forms of AE191 and is 
currently preferred to BB-UVB because it is less erythemogenic, 
while high-dose UVA1 has been prescribed for more severe 
phases.192 Furthermore, as highlighted in a recent study, there are 
a small but significant proportion of psoriasis and AE patients 
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who do not tolerate NB-UVB but demonstrate an excellent 
clinical response to BB-UVB.193 
Practical aspects of AE treatment 
In practice, the choice of a certain UV treatment is limited by the 
availability of the phototherapy equipment: e.g., UVA1 devices 
are expensive to buy and to maintain. The biggest drawbacks of 
UV therapy are that the patient must travel between 3 and 5 times 
per week and for 6–12 weeks to a site that offers this therapy. In 
addition, UV light does not effectively treat hairy areas as scalp 
and skin folds. As a rule, phototherapy is not indicated in the acute 
stage of AE (except UVA1, which is also effective in managing 
AE flares), but is more apt to treat chronic, pruritic, lichenified 
forms and should not be prescribed in those patients who 
experience a worsening of AE during sun exposure. 
At the beginning of phototherapy, a co-medication of topical 
steroids and emollients should be considered to prevent a possible 
flare-up. UV therapy has to comply with special requirements 
with regard to personnel, documentation, UV protection 
especially of the eyes, contraindications and technical aspects. 
In practice, when prescribed, phototherapy is usually a part of 
a total treatment plan; i.e., a second-level treatment used 
especially in adults and much less in children. Phototherapy can 
improve and even clear AE; it can decrease bacterial colonization 
and reduce the strength and/or the amount of topical 
antiinflammatory drugs needed, but the beneficial effects vary 
from person to person. 
Summary of evidence 
Narrowband UVB has a better safety and efficacy profile 
compared to broadband UVB. (1a) 
Medium-dose UVA1 is similar in efficacy to narrowband 
UVB. (1b) 
High-dose UVA1 is more effective in severe phases of AE. (1b) 
All UV treatments pose theoretically a long-term risk of 
development of skin ageing and skin cancer, which is best 
demonstrated for PUVA. (2a) 
New devices such as 308-nm excimer laser or visible blue light 
therapy may expand therapeutic options, but have not been 
assessed properly in AE. (-) 
Recommendations 
• Medium-dose UVA1 and narrowband UVB are 
recommended for the treatment of AE in adult patients. 
(1b, A) 
• Narrowband UVB is preferred over broadband UVB for 
AE treatment if available. (1a, A) 
• Co-treatment with topical steroids and emollients should 
be considered at the beginning of phototherapy to prevent 
flare-up. (C) 
• PUVA therapy is not a first-choice therapy for safety 
profile reasons. (1b, A) 
• New devices such as 308-nm excimer laser are not 
recommended for the treatment of AE patients. (-,D) 
• Although phototherapy is rarely used in prepubertal 
children, it is not contraindicated; its use depends rather 
on feasibility and equipment (NB-UVB). (-,D) 
Antipruritic therapy 
Itch is the most important clinical symptom in AE, with particular 
impact on emotional dimensions of perception as compared to 
other pruritic dermatoses.194,195 Concerning pruritus 
accompanying AE, only few studies investigated the antipruritic 
effect only. Pruritus was in most studies part of the total symptom 
score, such as in SCORAD or PO-SCORAD.4,6 For example, 
topical and systemic corticosteroids, topical calcineurin 
inhibitors, cyclosporine and UV irradiation have significant 
influence on pruritus, while only single studies specifically 
investigated the relief of pruritus intensity. 
Antipruritic therapy in AE is multidimensional treating the 
symptom itself, the contributing factors such as dry skin, 
inflammation and the related scratch lesions. Therefore, several 
general measures can also be recommended (see: ‘Basic Therapy’ 
and ‘Psychosomatic counselling’). 
Topical therapy 
Glucocorticosteroids Topical corticosteroids have anti-
inflammatory activity rather than acting as direct antipruritic 
agents.196 However, several studies described the anti-
inflammatory effect of topical corticosteroids in AE, in which 
pruritus was one parameter among others studied. Recent meta-
analysis revealed six RCT with topical corticosteroids (desonide 
hydrogel 0.05%, clobetasol propionate lotion, fluticasone 
propionate 0.05% cream, prednicarbate 0.25% ointment, 
hydrocortisone 1% and methylprednisolone aceponate 0.1% 
cream) and showed that those agents significantly reduce itch in 
AE patients by 34% in comparison with the vehicle usage.197 
Topical corticosteroids have a rapid antipruritic effect and can 
also be used in ‘proactive’ therapy.108 
Calcineurin inhibitors Topical calcineurin inhibitors relieve 
significantly pruritus in AE. Itch is completely relieved after the 
first days of treatment in both adults and children. Twenty-two 
RCTs were meta-analysed (16 – pimecrolimus 1% cream, 3 – 
tacrolimus 0.3% ointment, 1 – tacrolimus 0.1% ointment, 1 – 
European guidelines for treatment of atopic eczema - part I 675 
 
tacrolimus 0.03% and 1 – tacrolimus 0.01% ointment). Topical 
calcineurin inhibitors appeared to reduce AE itch significantly by 
36% compared to vehicle application.197 Pimecrolimus blocks via 
TRPV1 the re-accumulation and synthesis of substance P (SP), a 
major mediator of pruritus in inflammatory skin lesions. 
Antihistamines 5% doxepin cream exhibited antipruritic effects in 
three controlled studies in AE; one RCT assessed the efficacy of 
cromoglycate 4% lotion.197 The meta-analysis of those studies 
documented that the use of topical antihistamines markedly 
reduced itch of AE by 27% in patients in comparison with the 
vehicle. However, topical doxepin therapy is not licensed and not 
used in any European country due to an increased risk of contact 
allergy, especially when the treatment exceeds eight days. 
Cannabinoid receptor agonist Topical cannabinoid receptor 
agonists have been described to exhibit antipruritic and analgesic 
properties. One cosmetic product containing the cannabinoid 
agonist N-palmitoylethanolamine was used in a multicentre, large 
cohort, open-label study as adjuvant treatment in AE.74 A total of 
2456 patients including over 900 children applied the cream twice 
daily. Pruritus and the need to use corticosteroids were reduced 
up to 60%. 
Opioid receptor antagonists One double-blind, vehicle-controlled, 
randomized crossover trial was performed with topical l-opioid 
receptor antagonist nalmefene. The drug was used during two 7-
day periods separated by the washout period. The study did not 
show significant efficacy in reducing the itch intensity in AE.198 
Polidocanol Case series described the efficacy of a combination of 
the anaesthetic polidocanol and 5% urea.199 In children with AE, 
the combination showed a pruritus improvement of 30% in 
comparison with an emollient.200 Polidocanol is not licensed for 
AE in Europe, but OTC products are available. 
Anaesthetics Local anaesthetics such as benzocaine, lidocaine, as 
well as a mixture of prilocaine and lidocaine are widely used as 
short-term effective topical antipruritics. In experimental studies, 
the antipruritic effect of local anaesthetics was demonstrated in 
AE.201 None of these substances is licensed for AE in Europe, but 
some OTC products are available. 
Capsaicin Capsaicin is a naturally occurring alkaloid and the 
principal pungent of hot chilli peppers. Capsaicin binds to the 
TRPV1 ion channel, which is present on many itch-mediating C-
fibres. Capsaicin has been advocated to be antipruritic in various 
dermatoses. Concerning AE, experimental studies 202 and case 
series 203 report on clear itch reduction. No controlled study has 
been published. 
Summary of evidence 
There is evidence that topical corticosteroids are effective in the 
initial phase of AE exacerbation to control pruritus. (1a) 
There is evidence that topical calcineurin inhibitors are 
effective in AE until clearance of eczema to control pruritus. (1a) 
There is not enough RCT evidence to demonstrate the efficacy 
of topical antihistamines, including doxepin in the treatment of 
AE itch. (1a) 
There is no evidence from RCTs that the topical cannabinoid 
receptor agonist N-palmitoylethanolamine is effective as an 
adjuvant antipruritic therapy in AE. 4 
There is no evidence that the topical l-opioid receptor 
antagonist nalmefene is effective in the management of pruritus 
in AE. (2b) 
There is no evidence that topical anaesthetics and capsaicin is 
an effective adjuvant antipruritic therapy in AE. 4 
Recommendations 
• Topical corticosteroids are recommended to control 
pruritus in the initial phase of AE exacerbation. (1a,A) 
• Topical calcineurin inhibitors are recommended to control 
pruritus in AE until clearance of eczema. (1a,A) 
• Topical polidocanol may be used to reduce pruritus in AE 
patients. (-,D) 
• Routine clinical use of topical antihistamines including 
doxepin, topical cannabinoid receptor agonists, topical l-
opioid receptor antagonists or topical anaesthetics cannot 
be recommended as an adjuvant antipruritic therapy in AE. 
(4,C) 
• There is not enough data available to recommend the use 
of capsaicin in management of itch in AE patients. (4,B) 
UV therapy 
UV irradiation relieves pruritus in AE, which has been 
demonstrated in several studies. A recent systematic review of 19 
available RCTs suggests the usage of narrowband UVB and 
UVA1 as the most effective in the treatment of AE, including 
reduction in itch intensity.204 There is no ‘anti-itch-specific’ data 
for UV therapy available, which would differ from the general 
recommendations for UV treatment of AE. (See chapter ‘UV 
therapy’). 
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Recommendations 
• There is evidence that UV therapy can be used in AE to 
relief pruritus. Narrowband UVB and UVA1 seem to be 
most preferable treatment modalities. (2a,B) 
Systemic therapy 
Antihistamines Antihistamines (AH) have been used for decades, 
in an attempt to relieve pruritus in patients with AE. However, 
only a few randomized controlled trials have been conducted and 
they have in the majority shown only a weak or no effect in 
decreasing pruritus.205–213 According to a Cochrane search, 
randomized controlled trials investigating the efficacy of AH 
monotherapy in eczema patients are lack- 
ing.214 
The first generation of sedative AH such as hydroxyzine, 
clemastine fumarate and dimethindene maleate may allow a better 
sleep in acute situations with exacerbations of eczema (evidence 
level D). A significant, but clinically small, antipruritic effect of 
fexofenadine 60 mg twice daily has been described.215 An effect 
on itch of a high dosage of 20 to 40 mg cetirizine daily has been 
observed, but this effect was primarily attributed to sedation.211 In 
the recent meta-analysis of antipruritics in AE,197 only one RCT 
study on systemic AH fulfilled the criteria for inclusion and did 
not show significant improvement of itch in comparison with 
placebo.211 
In general, AH are safe to use, also for a long period of time.216 
There are limited evidence-based data for the antipruritic effect of 
AH (H1 antagonists) in AE in general, and the effect of both first- 
and second-generation AH on pruritus in patients suffering from 
AE is very limited. AH may decrease urticaria when associated 
with AD, but this is rarely seen in clinical reality. The ETAC 
paediatric cetirizine studies showed an effect of AH on food-
induced urticaria.217 (See also chapter ‘Other systemic treatment’) 
Apremilast The oral inhibitor of phosphodiesterase 4 (PDE4) 
apremilast is discussed in part II of the guideline (see chapter 
‘other systemic treatment’). 
Leukotriene receptor antagonists The leukotriene receptor 
antagonists zafirlukast and zileuton are discussed in part II of the 
guideline (see chapter ‘other systemic treatment’). 
Opioid receptor antagonists The l-opioid receptor antagonist 
nalmefene was applied in randomized controlled studies in AE. A 
dosage of 10 and 20 mg each once per day showed significant 
relief of pruritus in three studies.218–220 In open-label trials and one 
double-blind, placebo-controlled study trial, the only orally active 
l-opioid antagonist naltrexone 25–150 mg per day showed 
considerable antipruritic effects.221,222 Common sideeffects 
include anxiety, arthralgia, dizziness, drowsiness, fatigue, 
vomiting and headache. None of these substances is currently 
licensed for the treatment of AE itch. 
Selective serotonin reuptake inhibitors The antipruritic effect of the 
selective serotonin reuptake inhibitors paroxetine and 
fluvoxamine was investigated in an open-label trial in 
dermatological patients. A few patients with pruritus due to AE 
were included, who responded with considerable reduction in 
pruritus. In these patients, the pruritus was reduced about half in 
intensity (maximal antipruritic effect score, 45.0 + /- 
7.1%).223 
Cyclosporine A See chapter ‘Systemic Immunosuppression’. 
Intravenous Immunoglobulin therapy See chapter ‘Other systemic 
treatment’. 
Mycophenolate mofetil See chapter ‘Systemic 
Immunosuppression’. 
Nemolizumab See chapter ‘Biologics’. 
Summary of evidence 
There is conflicting evidence regarding efficacy of antihistamines 
(H1 antagonists) for the treatment of pruritus in AE, with the 
majority of studies showing only a weak or no effect on pruritus. 
Antihistamines in general, and especially second-generation 
agents, show a good safety profile (1b). 
The opioid receptor antagonists naltrexone and nalmefene may 
reduce itch in AE patients. Common side-effects include anxiety, 
arthralgia, dizziness, drowsiness, fatigue, vomiting and headache 
(1b). 
The selective serotonin reuptake inhibitors paroxetine and 
fluvoxamine may be effective in the treatment of AE-induced 
itch. Side-effects include constipation, diarrhoea, dizziness, 
drowsiness, ejaculatory and erectile dysfunction, decreased 
libido, insomnia, nausea and headache.4 
Recommendations 
• There is not enough evidence to support the general use 
of both first- and second-generation H1R antihistamines 
for the treatment of pruritus in AE. These may be tried 
for the treatment of pruritus in AE patients, if standard 
treatment with TCS and emollients is not sufficient. (1b, 
A) 
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• Long-term use of sedative antihistamines in childhood 
may affect sleep quality and is therefore not 
recommended. (-,D) 
• The opioid receptor antagonists naltrexone and 
nalmefene are not recommended for routine treatment of 
itch in AE patients. (-,D) 
• The selective serotonin reuptake inhibitors paroxetine 
and fluvoxamine are not recommended for routine 
treatment of itch in AE patients. (4,C) 
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